RadioMedix, Inc.
Website to be confirmed.
About RadioMedix, Inc.
RadioMedix, Inc. sits in Radiopharma Developer, a segment Bracken sees as structurally important to the radiopharma value chain.
Longer summary placeholder. Replace once Bracken finalizes the exhibitor profile copy.
What we're seeing
- Imaging Wire · 2026-09-28Radiomedix Inc closes Series C round to scale radiopharma manufacturingThe announcement comes amid tightening Mo-99 and Lu-177 supply.
- STAT News · 2026-02-15Radiomedix Inc publishes dosimetry data at SNMMI 2026Coverage notes the company's growing footprint in the radioligand therapy space.
- Nuclear Medicine Today · 2026-03-06Radiomedix Inc files IND for next-generation PSMA-targeted agentThe work builds on more than a decade of radiochemistry collaboration.
- PR Newswire · 2026-08-01Radiomedix Inc partners with academic center on Actinium-225 programThe work builds on more than a decade of radiochemistry collaboration.
- Reuters Health · 2026-05-20Radiomedix Inc expands cyclotron capacity to meet Lu-177 demandIndustry observers expect more activity of this kind in the run-up to SNMMI 2026.
Mocked while we wire the Exa integration. Headlines are illustrative.
What we expect to see at the booth
Booth talking points, demos, and announcements to watch for. Bracken analyst note coming.
A short Bracken POV will go here, drawing on our experience across this part of the radiopharma value chain. Specific commentary to be filled in by the team.
Editorial shown for exhibitors in Bracken's wheelhouse: radiopharma developers, isotope supply, CDMO/CMO, cyclotron, and imaging equipment.
Companies you may also want to visit.
Actinium Pharmaceuticals
Profile under construction. Check back closer to SNMMI 2026 for Bracken's read on Actinium Pharmaceuticals.
View profile →AtomVie Global Radiopharma Inc.
Profile under construction. Check back closer to SNMMI 2026 for Bracken's read on AtomVie Global Radiopharma Inc..
View profile →Bayer Oncology
Profile under construction. Check back closer to SNMMI 2026 for Bracken's read on Bayer Oncology.
View profile →